Clinical And Morphological Improvement Of Lupus Nephritis Treated With Rituximab

Open access


Aim: TO assess the effects of rituximab (RTM) therapy on clinical and morphologic activity of lupus nephritis (LN).

Material and methods: The study included 45 patients with confirmed diagnosis of systemic lupus erythematosus (SLE), unaffected by previously received standard therapy with glucocorticoids (GCs) and cytostatics. The disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K); to assess the LN activity we used the SLICC RA/RE index. Forty-five patients with LN were given puncture renal biopsy prior to prescribing RTM; 16 patients had repeated renal biopsy 1 year and more after beginning the anti-B-cell therapy. LN was graded histologically in accordance with the WHO classification (2003) with indices of activity (AI) and chronicity (CI).

Results: The predominant number of patients had class III - IV of LN. The repeated renal biopsies demonstrated that LN had undergone a transition into a more favourable morphologic class, which was associated, in most of these cases, with a positive therapeutic effect. The follow-up dynamics showed a statistically significant reduction of AI (p=0.006), and no statistically significant changes in the CI (p = 0.14).

Conclusion: The long-term follow-up in the study has showed that repeated courses of anti-B-cell therapy with RTM have a positive effect both on SLE activity and generally on the renal process. The reduction of the morphologic class of LN as assessed in the repeated renal biopsies is a convincing proof for this. Eleven out of 16 patients experienced transition of the morphologic class into a more favourable type, which in most cases was combined with lower AI (p = 0.006). We found no evidence of increase in the CI (p = 0.14).

1. Klyukvina NG, Nasonov EL, Nasonova VA. Systemic Lupus Erythematosus. In: Rheumatology, National Guidance Manual. Moscow: GEOTAR; 2008:419-46 (Russian).

2. Condon M, Ashby D, Pepper R, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.

3. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013;22(14): 1489-503.

4. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum 2013;62:2458-66.

5. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2013;25: 3586-92.

6. Ramos-Casals M, Garcia-Hemandez FJ, de Ramon E et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2013;28:468-76.

7. Furie R, Rovin R, Latnis KM, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009;60:429.

8. Gunnarsson I. Rituximab treatment in lupus nephritis – where do we stand. Lupus 2013;22:385-392.

9. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72.

10. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24:3717-23.

11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.

12. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29(2):288-91.

13. Radensca-Lopovok SG. Lupus nephritis. What is the latest in the morphologic diagnosis? Science and practice in rheumatology 2008;4:27-30 (Russian).

14. Petri M, Kasitanon N, Lee SS, et al. Renal activity Response exercise. Development of a Renal Activity ccore and Renal Response Index. Arthritis and Rheumatism 2008;58(6):1784-8.

15. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.

16. Josdottir T, Zickert A, Sundelin B, et al. Long-term follow-up in lupus nephritis patients treated with rituximab – clinical and histopathological response. Rheumatology (Oxford) 2013;52(5):847-55.

17. Davies RJ, Sangle SR, Jordan NP, et al. Rituximab in the treatment of resistant lupus nephritis: therapy in rapidly progressive crescentic lupus nephritis. Lupus 2013;22:574-82.

Folia Medica

The Journal of Medical University-Plovdiv

Journal Information

CiteScore 2017: 0.54

SCImago Journal Rank (SJR) 2017: 0.206


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 332 307 13
PDF Downloads 124 123 8